1
Bharat B Aggarwal, Michael A Palladino, Mohamed R Shalaby: Tumor necrosis factor antagonists and their use. Genentech, Diane L Marschang, August 18, 1998: US05795967 (168 worldwide citation)

Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis fac ...


2
Bharat B Aggarwal, Michael A Palladino, Mohamed R Shalaby: Tumor necrosis factor antagonists and their use. Genentech, Diane L Marschang, September 30, 1997: US05672347 (103 worldwide citation)

Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis fac ...


3
Christine W Czarniecki, Michael A Palladino, Eli Shefter: Method for the treatment of grafts prior to transplantation using TGF-.beta .. Genentech, Janet E Hasak, August 4, 1992: US05135915 (82 worldwide citation)

A method is provided for the treatment of grafts such as tissue or organs prior to transplantation into a suitable host. The grafts are incubated, coated, or perfused with TGF-.beta. for an effective time for the uptake of the agent into the grafts and induction of its biological effects. The thus-t ...


4
Michael A Palladino: Gamma interferon-interleukin-2 synergism. Genentech, Ginger R Dreger, January 21, 1992: US05082658 (46 worldwide citation)

Compositions containing therapeutically synergistic mixtures of purified gamma interferon and purified interleukin-2 are provided for treatment of tumor-bearing hosts. Preferably, the gamma interferon and interleukin-2 are obtained from recombinant cell synthesis.


5
Michael A Palladino, Stephen A Sherwin: Method and compositions for the treatment and prevention of septic shock. Genentech, Janet E Hasak, October 8, 1991: US05055447 (35 worldwide citation)

Methods and compositions are provided for the treatment or prophylaxis of septic shock caused by bacteremic infection. Therapeutically and prophylactically effective doses of transforming growth factor-beta are administered to patients, either alone or in combination with another therapeutic or prop ...


6
Yoshio Hayashi, Michael A Palladino Jr, Jennifer Grodberg: Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds. Nereus Pharmaceuticals, Knobbe Martens Olson & Bear, April 11, 2006: US07026322 (31 worldwide citation)

Methods of using a compound, its pharmaceutically acceptable salts, and/or its pro-drug esters, in isolated form, to treat cancer, and methods for isolating, for formulating, and for administering the compound, salt, and/or pro-drug ester as an antitumor agent, wherein the compound, salt, or pro-dru ...


7
Michael A Palladino, Bruce A Lee, William D Huse, Judith A Varner: Fivemer cyclic peptide inhibitors of diseases involving .alpha..sub.v .beta..sub.3. IXSYS Incorporated, Needle & Rosenberg P C, July 14, 1998: US05780426 (31 worldwide citation)

The present invention includes non-RGD cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. The inventive peptides are between five to about thirty amino acids in length and include the sequence (SEQ ID NO:8), Arg-Cys-Asp-Gly-X.sub.i where X.sub.i is any am ...


8
Michael A Palladino, Bruce A Lee, William D Huse, Judith A Varner: Sevenmer cyclic peptide inhibitors of diseases involving .alpha..sub.v .beta..sub.3. IXSYS Incorporated, Needle & Rosenberg P C, June 16, 1998: US05767071 (21 worldwide citation)

The present invention includes non-RGD, nine amino acid cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. These peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportuni ...


9
Michael A Palladino: Chemotactic assay for immunogenicity. Genentech, December 22, 1987: US04714674 (12 worldwide citation)

The in vitro chemotactic activity of recombinant protein compositions is a predictive test for in vivo immunogenicity. Recombinant synthesis methods and subsequent purification or processing techniques are modified in the light of the chemotactic assay results in order to reduce or enhance the in vi ...


10
Yoshio Hayashi, Michael A Palladino Jr, Jennifer Grodberg: Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof. Nereus Pharmaceuticals, Knobbe Martens Olson & Bear, June 20, 2006: US07064201 (11 worldwide citation)

Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to pr ...